CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Postmenopausal Patients With ER and/or PR Positive Metastatic Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00338728
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:26.062227+00:00
Published At: 2020-01-27T00:00:00+00:00
Record Updated At: 2020-01-27
Results Posted At: 2020-01-27
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen Receptor Positive", "KIT Positive", "PDGFR Positive", "Postmenopausal", "Progesterone Receptor Positive", "Prognostic Stage IV Breast Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-01-27"
protocolSection.identificationModule.nctId: "NCT00338728"
protocolSection.identificationModule.officialTitle: "Phase II Study of Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Postmenopausal Patients With ER and/or PR Positive Metastatic Breast Cancer"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2020-01-27"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.